Friday, September 15, 2023

*Bootcamp*

Program Director – Daniel Arber, MD
Chair of Pathology, University of Chicago Medicine
Donald West and Mary Elizabeth King Professor of Pathology at the University of Chicago

8:30-9:45 Check In, Breakfast, and Visit Sustaining Partners & Exhibitors

10:00-11:30 Welcome
Daniel Arber, MD /Timothy Allen, MD, JD
Bob McGonnagle, BA

Panel 1
Town and Gown Update 2023: Biomarkers and Targeted Therapies Across the Spectrum of Clinical Practice
Invited Panelists:

11:30-12:00 Break and Visit Sustaining Partners & Exhibitors

12:00-1:00 Panel 2
Reference Labs in Focus on Biomarker Testing
Invited Panelists:

1:00-2:00 Lunch with Table Topic Discussion and Visit Sustaining Partners & Exhibitors
2:00-3:00  Panel 3  
Winning Technologies Emerging?  
Invited Panelists:

3:00-4:00  Panel 4  
A Focus on Society Patients  
Invited Panelists:

4:00-5:00  Summation, Q&A, Reflections on the Day  
Timothy Allen, MD, JD / Daniel Arber, MD

All panels are designed to be fully interactive with attendees. Panel members, who may be subject to change, will offer only brief remarks, followed by questions and discussion. All tumor types, practice settings, biomarkers and technologies will be addressed in any and all panel sessions as they arise.
## CANCER BIOMARKERS

### CONFERENCE VI • #CBCVI

<table>
<thead>
<tr>
<th>Saturday, September 16, 2023</th>
<th>Sunday, September 17, 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>7 a.m. – 5 p.m.</td>
<td>7 a.m. – 12:30 p.m.</td>
</tr>
</tbody>
</table>

*Pre-Conference Bootcamp (Non-CME) Friday, September 15, 2023 – 8:30 a.m. – 5 p.m.*

---

**David Rubenstein Forum • Chicago, IL**

### Saturday, September 16, 2023

**Program Director – Daniel Arber, MD**  
Chair of Pathology, University of Chicago Medicine  
Donald West and Mary Elizabeth King Professor of Pathology at the University of Chicago

**7:00-8:00**  
Check In, Breakfast and Visit Sustaining Partners & Exhibitors

**8:00-8:30**  
Keynote Address: Biomarkers in Myeloid Neoplasms  
Daniel Arber, MD  
Donald West and Mary Elizabeth King Professor, Chairman, Department of Pathology, University of Chicago

**8:30-9:00**  
Biomarker Testing in Small Specimens (biopsy vs. FNA)  
Sinchita Roy Chowduri, MD

**9:00-9:30**  
Predictive Biomarkers in Malignant Gynecologic Neoplasms  
Ricardo Lastra, MD

**9:30-10:00**  
Molecular Biomarker Testing in Genitourinary Neoplasms  
Donna Hansel, MD

**10:00-10:30**  
Break and Visit Sustaining Partners & Exhibitors

**10:30-11:00**  
The Second Revision of the Lung Cancer Molecular Testing Guidelines  
Neal Linderman, MD

**11:00-11:30**  
Molecular and Genomic Biomarkers of Gastrointestinal Cancers for Precision Therapies
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:30-12:00</td>
<td>Predictive Biomarkers for Immunotherapy in Lung Cancer</td>
</tr>
<tr>
<td></td>
<td>Mari Mina-Kenudson, MD</td>
</tr>
<tr>
<td></td>
<td>Director, Pulmonary Pathology, Massachusetts General Hospital, Professor of Pathology, Harvard Medical School</td>
</tr>
<tr>
<td>12:00-12:30</td>
<td>Panel Discussion</td>
</tr>
<tr>
<td>12:30-1:30</td>
<td>Lunch and Visit Sustaining Partners &amp; Exhibitors</td>
</tr>
<tr>
<td>1:30-2:00</td>
<td>Biomarkers in Colorectal Carcinoma: What’s New in 2023?</td>
</tr>
<tr>
<td></td>
<td>Rhonda Yantiss, MD</td>
</tr>
<tr>
<td>2:00-2:30</td>
<td>Update on Dermatopathologic Molecular Biomarker Testing</td>
</tr>
<tr>
<td></td>
<td>Sara Shalin, MD</td>
</tr>
<tr>
<td>2:30-3:00</td>
<td>Biomarkers in Breast Cancer</td>
</tr>
<tr>
<td></td>
<td>Deborah Dillon, MD, PhD</td>
</tr>
<tr>
<td></td>
<td>Director, Breast Biorepository and Clinical Trials Lab</td>
</tr>
<tr>
<td></td>
<td>Dana-Farber Cancer Institute, Harvard Medical School</td>
</tr>
<tr>
<td>3:00-3:30</td>
<td>Break and Visit Sustaining Partners &amp; Exhibitors</td>
</tr>
<tr>
<td>3:30-4:00</td>
<td>Genetic Molecular Biomarker Testing</td>
</tr>
<tr>
<td></td>
<td>Jonathan Nowak, MD</td>
</tr>
<tr>
<td>4:00-4:30</td>
<td>Panel Discussion/Day 1 Wrap Up</td>
</tr>
<tr>
<td>4:30</td>
<td>Adjourn</td>
</tr>
</tbody>
</table>
Sunday, September 17, 2023

Program Director – Timothy Allen, MD, JD
Chair of Pathology, Oakland University William Beaumont School of Medicine
Chief of Pathology Service line – Beaumont Health, Physician Executive,
Pathology – Beaumont Medical Group, Chief of Pathology – Beaumont Royal Oak Hospital

7:00-8:00 Check In, Breakfast and Visit Sustaining Partners & Exhibitors

8:00-8:30 A Contemporary Biomarker-Driven Approach to Diffuse Glioma Diagnosis
Daniel Brat, MD
Magerstadt Professor and Chair, Department of Pathology, Northwestern University
Feinberg School of Medicine

8:30-9:00 Update on Molecular Biomarker Testing in Neuropathology
Jose Otero, MD

9:00-9:30 Reflex Biomarker Testing for Early Stage Lung Cancer: Babinski or Boon?
Eric Bernicker, MD

9:30-10:00 Drug Resistance to Personalized Therapy in Gastrointestinal Cancers
Namrata Setia, MD

10:00-10:30 Biomarkers in T-Cell Lymphoma
Andy Feldman, MD

10:30-11:00 Panel Discussion
Moderator: Timothy Allen, MD, JD
Chair of Pathology, Oakland University William Beaumont School of Medicine
Chief of Pathology Service line – Beaumont Health, Physician Executive,
Pathology – Beaumont Medical Group, Chief of Pathology – Beaumont Royal Oak Hospital

11:00-11:30  **Break and Visit Sustaining Partners & Exhibitors**

11:30-12:00  **Update on Lung Cancer Biomarker Testing**
Alain Borczuk, MD
Vice Chairman and Director of Anatomic Pathology, Chief of Thoracic Pathology,
Weill Cornell Medicine

11:30-12:00  **Molecular Aspects of Mesothelioma**
Lucian Chirieac, MD
Associate Professor of Pathology, Harvard Medical School
Brigham and Women's Hospital

12:00- 12:30  **Biomarkers in B-cell Lymphoma**
Genevieve (Eve) Crane, MD, PhD
Assistant Professor of Pathology, Division of Immunopathology, Weill Cornell Medicine,
Weill Cornell Medical College

Predict emerging technologies that may improve patient care by identifying early evidence of treatment failure or disease evolution.

12:30  **Adjourn** - 30 minutes have been allotted for the completion of the course evaluation. Please complete the evaluation/claim your credit by Wednesday, September 14, 2023. The evaluation time is incorporated into the last session of the day.
Disclosure

No planners or speakers have any relevant conflicts of interest to disclose with the exception of Dr. Daniel Arber, who is a consultant for Jazz Pharma. Any potential conflicts of interest have been mitigated through an attestation that he will not present recommendations regarding the use of drugs or devices from companies with which he has a financial relationship. Dr. Mari Mino-Kenudson is a consultant for AstraZeneca, BMS, Sanofi, and Janssen Oncology. She also receive royalties from Elsevier. Any potential conflicts of interest have been mitigated through an attestation that she will not present recommendations regarding the use of drugs or devices from companies with which she have a financial relationship. Dr. Deborah Dillon is a consultant/member of the Academic Advisory Board for Oncology Analytics and have received a research grant from Canon, Inc. Any potential conflicts of interest have been mitigated through an attestation that she will not present recommendations regarding the use of drugs or devices from companies with which she have a financial relationship. Dr. Jonathan Nowak received funding for pilot technology feasibility studies from NanoString, Illumina, and Akoya Biosciences and a research grant from Akoya Biosciences. Any potential conflicts of interest have been mitigated through an attestation that he will not present recommendations regarding the use of drugs or devices from companies with which he have a financial relationship.

Continuing Educational Credit

Physician Credit
The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Chicago Pritzker School of Medicine designates this live activity for a maximum of 12 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Pathology Lifelong Learning (CME) Credit
This activity has been registered to offer credit in the American Board of Pathology’s Continuing Certification program. Successful completion of this activity, which includes participation in the evaluation component, enables the participant to earn up to 12 CME credits. Participants will earn credits equivalent to the amount of AMA PRA Category 1 Credits™ claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABPath Lifelong Learning (CME) credit.

Other Health Professional Credit
Other healthcare professionals will receive a Certificate of Participation. For information on the applicability and acceptance of Certificates of Participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME, please consult your professional licensing board.